CM
MRTX

Capula Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Capula Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,680
Closed -$458K – 697
2023
Q2 		$458K Buy
+12,680
New +$522K 0.01% 339

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capula Management's MRTX Position: Q3 2023 in Review

Capula Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 12,680 shares — an estimated $458K sold.

Capula Management first reported a position in MRTX in Q2 2023 and held it in 1 quarter. The position peaked at $458K in Q2 2023. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Capula Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Capula Management sold 12,680 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $458K.
  • Capula Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Capula Management's Mirati Therapeutics, Inc. Common Stock position peaked at $458K in Q2 2023.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Capula Management's 13F filing for Q3 2023, filed 3 Nov 2023.